Hepatic UDP-glucuronosyltransferases in liver injury

Abstract

Abstract: Liver is the most important metabolic organ in human, including the vast majority of metabolic enzymes involving phase Ⅰ and phase Ⅱ and playing an important role on detoxification of many endogenous and exogenous substances.UDP-glucuronosyltransferases (UGT)is the most important phase Ⅱ metabolic enzyme that catalize glucuronidation in human, as compared with the CYP450 enzymes, study of UGTs lags behind, especially, the state of UGTs in liver injury is still poorly understood.This review summarizes latest studies of the UGTs in gene, protein structure and function, distribution in liver and relationship with the liver disease, then we discuss the effects of several common liver injury on hepatic UGT and glucuronidation.It will provide more reliable reference in durg metabolism in liver injury and guide the clinical rational use of drugs.

Key words: liver, UDP-glucuronosyltransferases, phase Ⅱ metabolism;, liver injury

CLC Number:

R969.1

JIANG Shan, HAO Hai-ping, WANG Guang-ji. Hepatic UDP-glucuronosyltransferases in liver injury[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1321-1328.

References

[1] Nagar S, Remmel RP.Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer[J]. Oncogene, 2006, 25(11):1659-1672.
[2] FinelM, Kurkela M.The UDP-glucuronosyltransferases as oligomeric enzymes[J].2008, 9(1):70-76.
[3] Bock KW, Kö hle C.Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes:Advances and open questions[J].Biochem pharmacol, 2009, 77(9):1458-1465.
[4] Nakamura A, Nakajima M, Yamanaka H, et al.Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines[J].Drug Metab Dispos, 2008, 36(8):1461-1464.
[5] Hoyumpa AM, Schenker S.Is glucuronidation truly preserved in patients with liver disease[J] ? Hepatology, 1991, 13(4):786-795.
[6] Knapp SA, Green MD, Tephly TR, et al.Immunohistochemical demonstration of isozyme-and strain specific differences in the intralobular Iocalizations and distributions of UDP-glucuronosyltransferases in livers of untreated rats[J].Mol Pharmacol, 1988, 33(1):14-21.
[7] Debinski HS, Lee CS, Danks JA, et al.Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury[J].Gastroenterology, 1995, 108(5):1464-1469.
[8] Kardon T, Coffey MJ, Bánhegyi G, et al.Transcriptional induction of bilirubin UDP-glucuronosyltransrase by ethanol in rat liver[J].Alcohol, 2000, 21(3):251-257.
[9] Li Y, Wang K, Yu T, et al.The expression of uridine diphosphate glucuronosyltransferase mRNA regulated by alcohol[J].Zhonghua Gan Zang Bing Za Zhi, 2001, 9(3):172-174.
[10] Bichlmaier I, KurkelaM, Joshi T, et al.Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives[J].J Med Chem, 2007, 50(11):2655-2664.
[11] Soars MG, Petullo DM, Eckstein JA, et al.Wrighton An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes[J].Drug Metab Dispos, 2004, 32(1):140-148.
[12] Catania VA, Luquita MG, Sánchez Pozzi EJ, et al.Effect of spironolactone on the expression of rat hepatic UDP-glucuronosyltransferase[J].Biochem Pharmacol, 2003, 66(1):171-177.
[13] Jeong H, Choi S, Song JW, et al.Regulation of UDPglucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination[J].Xenobiotica, 2008, 38(1):62-75.
[14] Buckley DB, Klaassen CD.Mechanism of gender-divergent UDP-glucuronosy ltransferase mRNA expression in mouse liver and kidney[J].Drug Metab Dispos, 2009, 37(4):834-840.
[15] Usui T, Kuno T, Mizutani T.Induction of human UDPglucuronosyltransferase 1A1 by cortisol-GR[J].Mol Biol Rep, 2006, 33(2):91-96.
[16] Kostrubsky SE, Sinclair JF, Strom SC, et al.Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosy ltransferases in cultured human hepatocytes[J].Toxicol Sci, 2005, 87(1): 146-155.
[17] Huang YY, Huang MJ, Yang SS, et al.Variations in the UDP-glucuronosyltransferase 1A1 gene for the development of unconjugated hyperbilirubinemia in Taiwanese[J]. Pharmacogenomics, 2008, 9(9):1229-1235.
[18] Philipp T, Durazzo M, Trautwein C, et al.Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D[J].Lancet, 1994, 344(8922):578-581.
[19] Howden CW, Birnie GG, Brodie MJ.Drug metabolism in liver disease[J].Pharmacol Ther, 1989, 40(3):439-479.
[20] Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al.Temazepam clearance unaltered in cirrhosis[J].Am J Gastroenterol, 1986, 81(1):80-84.
[21] Patwardhan RV, Johnson RF, Hoyumpa AM, et al.Normal metabolism of morphine in cirrhosis[J].Gastroenterology, 1981, 81(6):1006-1011.
[22] Crotty B, Watson KJR, Desmond PV, et al.Hepatic extraction of morphine is impaired in cirrhosis[J].Eur J Clin Pharmacol, 1989, 36(5):501-506.
[23] Gerkens JF, Desmond PV, Schenker S, et al.Hepatic and extrahepatic glucuronidation of lorazepam in the dog[J].Hepatology, 1981, 1(4):329-335.
[24] Richardson TA, Sherman M, Kalman D, et al.Expression of UDP-Glucuronosyltransferase isoform mRNAs during inflammation and infection in mouse liver and kidney[J]. Drug Metab Dispos, 2006, 34(3):351-353.
[25] CongiuM, MashfordML, Slavin JL, et al.UDP glucuronosyltransferase mRNA levels in human liver disease[J]. Drug Metab Dispos, 2002, 30(2):129-134.
[26] Monshouwer M, Witkamp RF.Cytochromes and cytokines:changes in drug disposition in animals during an acute phase response:a mini-review[J].Vet Q, 2000, 22(1):17-20.
[27] Richardson TA, Morgan ET.Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice[J].J Pharmacol Exp Ther, 2005, 314(2):703-709.
[28] Richardson TA, ShermanM, Antonovic L, et al.Hepatic and renal cytochrome P450 gene regulation during Citrobacter rodentium infection in wild-type and toll-like receptor 4 mutant mice[J].Drug Metab Dispos, 2006, 34(3):354-360.
[29] Monshouwer M, Witkamp RF, Nujmeijer SM, et al.Suppression of cytochrome P450- and UDP glucuronosyl transferase- dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes[J].Toxicol Appl Pharmacol, 1996, 137(2):237-244.
[30] Strasser SI, Mashford ML, Desmond PV.Regulation of uridine diphosphate glucuronosy ltransferase during the acute-phase response[J].J Gastroenterol Hepatol, 1998, 13(1):88-94.
[31] Wyles DL, Gerber JG.Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction[J].Clin Infect Dis, 2005, 40(1):174-181.
[32] Furlan V, Demirdjian S, Bourdon O, et al.Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers[J].J Pharmacol Exp Ther, 1999, 289(2):1169-1175.
[33] Debinski HS, Mackenzie PI, Lee CS, et al.UDP glucuronosyltransferase in the cirrhotic rat liver[J].J Gastroenterol Hepatol, 1996, 11(4):373-379.
[34] Buckley DB, Klaassen CD.Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2[J].Drug Metab Dispos, 2009, 37(4):847-856.
[35] Shelby MK, Klaassen CD.Induction of rat UDP-glucuronosy ltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways[J].Drug Metab Dispos, 2006, 34(10):1772-1778.
[36] Osabe M, Sugatani J, Fukuyama T, et al.Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator -activated receptor αin male rats fed a high-fat and high -sucrose diet[J].Drug Metab Dispos, 2008, 36(2):294-302.
[37] Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, et al.Expression of the Human UGT1 Locus in Transgenic Mice by 4-Chloro-6-(2, 3-xylidino)-2-pyrimidinylthioacetic Acid (WY-14643)and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor αActivation[J].Drug Metab Dispos, 2007, 35(3):419-427.
[38] Gardner-Stephen DA, Mackenzie PI.Liver-enriched transcription factors and their role in regulating UDP glucuronosy ltransferase gene expression[J].Curr Drug Metab, 2008, 9(5):439-452.
[39] 张利, 周宏灏.孤儿核受体对尿苷二磷酸葡萄糖醛酸转移酶基因转录调节的研究进展[J].中国临床药理学与治疗学, 2007, 12(9):974-979.
[40] Witassek F, Bircher J, Huguenin P, et al.Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver[J].Hepatology, 1983, 3(3):415-422.
[41] Forrest JA, Adrienssens P, Finlay son ND, et al.Paracetamol metabolism in chronic liver disease[J].Eur J Clin Pharmacol, 1979, 15(6):427-431.
[42] Hasselstrom J, Erikson S, Persson A, et al.The metabolism and bioavailability of morphine in patients with severe liver cirrhosis[J].Br J Clin Pharmacol, 1990, 29(3):289-297.
[43] Kundu R, Dasgupta S, Biswas A, et al.Cajanus cajan Linn.(Leguminosae) prevents alcohol-induced rat liver damage and augments cytoprotective function[J].J Ethnopharmacol, 2008, 118(3):440-447.
[44] Villanueva SS, RuizML, Ghanem CI, et al.Hepatic synthesis and urinary elimination of acetaminophen glucuronide are exacerbated in bile duct-ligated rats[J].Drug Metab Dispos, 2008, 36(3):475-480.
[45] Hasegawa Y, Kishimoto S, Takahashi H, et al.Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis[J].J Pharm Pharmacol, 2009, 61(9):1205-1210.